Exploring the pharmacokinetics of second-generation cephalosporin, cefaclor: a systematic review in healthy and diseased populations

References

• Al Hammadi A, Al-Haddab M, Sasseville D. 2006. Dermatologic treatment during pregnancy: practical overview. J Cutan Med Surg. 10(4):183–192. doi: 10.2310/7750.2006.00043.
   PubMed Web of Science ®Google Scholar
• Arsalan A, Ahmad I, Ali SA. 2017. Cefaclor: clinical, biochemical, analytical and stability aspects. Adv Med Biol. 123:1–52.
   Google Scholar
• Ashfaq S, Nawaz R. 2009. Elimination kinetics of cefaclor in male human beings. Int J Biol Biotech. 6(3):183–186.
   Google Scholar
• Bachmann K, Schwartz J, Forney R, Jr, Jauregui L. 1986. Impact of cefaclor on the pharmacokinetics of theophylline. Ther Drug Monit. 8(2):151–154. doi: 10.1097/00007691-198606000-00004.
   PubMed Web of Science ®Google Scholar
• Bank D. (n.d.). https://go.drugbank.com/drugs/DB00833.
   Google Scholar
• Barbhaiya R, Shukla U, Gleason C, Shyu W, Pittman K. 1990. Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Antimicrob Agents Chemother. 34(6):1210–1213. doi: 10.1128/AAC.34.6.1210.
   PubMed Web of Science ®Google Scholar
• Barbhaiya R, Shukla U, Gleason C, Shyu W, Wilber R, Martin R, Pittman K. 1990. Phase I study of multiple-dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother. 34(6):1198–1203. doi: 10.1128/AAC.34.6.1198.
   PubMed Web of Science ®Google Scholar
• Barbhaiya R, Shukla U, Gleason C, Shyu W, Wilber R, Pittman K. 1990. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother. 34(6):1204–1209. doi: 10.1128/AAC.34.6.1204.
   PubMed Web of Science ®Google Scholar
• Bergman HD, Jackson EA, Cardoni AA. 1980. Cefaclor (Ceclor®-Eli Lilly and Company). Drug Intel Clin Pharm. 14(1):11–16. doi: 10.1177/106002808001400103.
   Google Scholar
• Brumfitt W, Hamilton-Miller J. 1999. Cefaclor into the millennium. J Chemother. 11(3):163–178. doi: 10.1179/joc.1999.11.3.163.
   PubMed Web of Science ®Google Scholar
• Cattrall JWS, Robinson AV, Kirby A. 2018. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. 37(12):2285–2291. doi: 10.1007/s10096-018-3371-y.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang B, Lou H, Yu L, Ruan Z. 2012. Bioequivalence studies of 2 oral cefaclor capsule formulations in Chinese healthy subjects. Arzneimittelforschung. 62(3):134–137. doi: 10.1055/s-0031-1298012.
   PubMed Web of Science ®Google Scholar
• Chin K, Kerr M, Cockburn F, McAllister T. 1981. A pharmacological study of cefaclor in the newborn infant. Curr Med Res Opin. 7(3):168–170. doi: 10.1185/03007998109114258.
   PubMed Web of Science ®Google Scholar
• Cooke A, Smith D, Booth A. 2012. Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qual Health Res. 22(10):1435–1443. doi: 10.1177/1049732312452938.
   PubMed Web of Science ®Google Scholar
• de la Peña A, Brunner M, Eichler HG, Rehak E, Gross J, Thyroff‐Friesinger U, Müller M, Derendorf H. 2002. Comparative target site pharmacokinetics of immediate‐and modified‐release formulations of cefaclor in humans. J Clin Pharmacol. 42(4):403–411.
   PubMed Web of Science ®Google Scholar
• Derry JE. 1981. Evaluation of cefaclor. Am J Hosp Pharm. 38(1):54–58. doi: 10.1093/ajhp/38.1.54.
   PubMedGoogle Scholar
• Glynne A, Goulbourn R, Ryden R. 1978. A human pharmacology study of cefaclor. J Antimicrob Chemother. 4(4):343–348. doi: 10.1093/jac/4.4.343.
   PubMed Web of Science ®Google Scholar
• Hampel B, Lode H, Wagner J, Koeppe P. 1982. Pharmacokinetics of cefadroxil and cefaclor during an eight-day dosage period. Antimicrob Agents Chemother. 22(6):1061–1063. doi: 10.1128/AAC.22.6.1061.
   PubMed Web of Science ®Google Scholar
• Higgins J. 2011. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, Cochrane Statistical Methods Group 2011. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343(oct18 2):d5928–d5928. doi: 10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Hodges GR, Liu C, Hinthorn DR, Harms JL, Dworzack DL. 1978. Pharmacological evaluation of cefaclor in volunteers. Antimicrob Agents Chemother. 14(3):454–456. doi: 10.1128/AAC.14.3.454.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang W, Miao L. 2014. Determination of cefaclor by UPLC–MS-MS for a Chinese pharmacokinetic study. J Chromatogr Sci. 52(7):636–640. doi: 10.1093/chromsci/bmt092.
   PubMed Web of Science ®Google Scholar
• James N, Donn K, Collins J, Davis I, Lloyd T, Hart R, Powell J. 1991. Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob Agents Chemother. 35(9):1860–1863. doi: 10.1128/AAC.35.9.1860.
   PubMed Web of Science ®Google Scholar
• Jeong S-H, Jang J-H, Cho H-Y, Lee Y-B. 2021. Population pharmacokinetic analysis of cefaclor in healthy Korean subjects. Pharmaceutics. 13(5):754. doi: 10.3390/pharmaceutics13050754.
   PubMed Web of Science ®Google Scholar
• Jiang B, Ruan Z, Lou H, Xu D, Yuan H. 2009. Determination of cefaclor in human plasma by reversed-phase high-performance liquid chromatography with UV detection and its application to the bioequivalence studies. Anal Lett. 42(14):2170–2179. doi: 10.1080/00032710903137467.
   Web of Science ®Google Scholar
• Karim S, Ahmed T, Monif T, Saha N, Sharma P. 2003. The effect of four different types of food on the bioavailability of cefaclor. Eur J Drug Metab Pharmacokinet. 28(3):185–190. doi: 10.1007/BF03190484.
   PubMed Web of Science ®Google Scholar
• Khan B, Ahmed T, Karim S, Monif T, Saha N, Sharma P. 2004. Comparative effect of different types of food on the bioavailability of cefaclor extended release tablet. Eur J Drug Metab Pharmacokinet. 29(2):125–132. doi: 10.1007/BF03190587.
   PubMed Web of Science ®Google Scholar
• Kitzes-Cohen R, Farin D, Marckovich J, Wasserman A, Gozlan I, Iaor A. 1997. A bioequivalence study of two formulations of cefaclor. Current Therapeutic Res. 58(6):352–360. doi: 10.1016/S0011-393X(97)80094-X.
   Web of Science ®Google Scholar
• Koguchi D, Murakami Y, Ikeda M, Dobashi M, Ishii J. 2020. Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study. BMC Urol. 20(1):38. doi: 10.1186/s12894-020-00605-6.
   PubMed Web of Science ®Google Scholar
• Korzeniowski OM, Scheld WM, Sande MA. 1977. Comparative pharmacology of cefaclor and cephalexin. Antimicrob Agents Chemother. 12(2):157–162. doi: 10.1128/AAC.12.2.157.
   PubMed Web of Science ®Google Scholar
• Koytchev R, Ozalp Y, Erenmemisoglu A, Tyutyulkova N, Gatchev E, Alpan RS. 2004. Studies on the bioequivalence of second generation cephalosporins: cefaclor capsules and suspension. Arzneimittelforschung. 54(09):583–587.
   PubMedGoogle Scholar
• Li M, Andrew MA, Wang J, Salinger DH, Vicini P, Grady RW, Phillips B, Shen DD, Anderson GD. 2009. Effects of cranberry juice on pharmacokinetics of β-lactam antibiotics following oral administration. Antimicrob Agents Chemother. 53(7):2725–2732. doi: 10.1128/AAC.00774-08.
   PubMed Web of Science ®Google Scholar
• Lin HS, Lin PT, Tsai YS, Wang SH, Chi CC. 2021. Interventions for bacterial folliculitis and boils (furuncles and carbuncles). Cochrane Database Syst Rev. 2(2):Cd013099.
   PubMedGoogle Scholar
• Lode H, Stahlmann R, Koeppe P. 1979. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother. 16(1):1–6. doi: 10.1128/AAC.16.1.1.
   PubMed Web of Science ®Google Scholar
• Long HA, French DP, Brooks JM. 2020. Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Res Methods Med Health Sci. 1(1):31–42. doi: 10.1177/2632084320947559.
   Google Scholar
• Lorenz LJ. 1981. Cefaclor. Analytical profiles of drug substances. Academic Press; p. 107–123.
   Google Scholar
• Mazzei T, Novelli A, Esposito S, Periti P. 2000. New insight into the clinical pharmacokinetics of cefaclor: tissue penetration. J Chemother. 12(1):53–62.
   PubMed Web of Science ®Google Scholar
• McCracken GH, Jr, Ginsburg CM, Clahsen JC, Thomas ML. 1978. Pharmacokinetics of cefaclor in infants and children. J Antimicrob Chemother. 4(6):515–521. doi: 10.1093/jac/4.6.515.
   PubMed Web of Science ®Google Scholar
• Men W, Dong Q, Shi W, Yao K. 2020. Serotype distribution and antimicrobial resistance patterns of invasive pneumococcal disease isolates from children in mainland China – a systematic review. Braz J Microbiol. 51(2):665–672. doi: 10.1007/s42770-019-00198-9.
   PubMed Web of Science ®Google Scholar
• Meyers BR. 2000. Cefaclor revisited. Clin Ther. 22(2):154–166. doi: 10.1016/S0149-2918(00)88477-5.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, Affrime MB. 1997. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. Pharmacotherapy. 17(1):121–125. doi: 10.1002/j.1875-9114.1997.tb03684.x.
   PubMed Web of Science ®Google Scholar
• Oguma T, Yamada H, Sawaki M, Narita N. 1991. Pharmacokinetic analysis of the effects of different foods on absorption of cefaclor. Antimicrob Agents Chemother. 35(9):1729–1735. doi: 10.1128/AAC.35.9.1729.
   PubMed Web of Science ®Google Scholar
• Patel A, Rai JP, Jain DK, Banweer J. 2012. Formulation, development and evaluation of cefaclor extended release matrix tablet. Int J Pharm Pharm Sci. 4(4):355–357.
   Google Scholar
• Peterson LR, Hall WH, Zinneman HH, Gerding DN. 1977. Standardization of a preparative ultracentrifuge method for quantitative determination of protein binding of seven antibiotics. J Infect Dis. 136(6):778–783. doi: 10.1093/infdis/136.6.778.
   PubMed Web of Science ®Google Scholar
• Platt R, Dreis MW, Kennedy DL, Kuritsky JN. 1988. Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole. J Infect Dis. 158(2):474–477. doi: 10.1093/infdis/158.2.474.
   PubMed Web of Science ®Google Scholar
• Price JR, Guran LA, Gregory WT, McDonagh MS. 2016. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 215(5):548–560. doi: 10.1016/j.ajog.2016.07.040.
   PubMed Web of Science ®Google Scholar
• Qu X, Deng Q, Li Y, Li P, Liu G, Wang Y, Liu Z, Yu S, Cheng Y, Zhou Y, et al. 2022. Pharmacokinetics and safety of the two oral cefaclor formulations in healthy Chinese subjects in the fasting and postprandial states. Front Pharmacol. 13:1012294. doi: 10.3389/fphar.2022.1012294.
   PubMed Web of Science ®Google Scholar
• Rotschafer J, Crossley K, Lesar T, Zaske D, Miller K. 1982. Cefaclor pharmacokinetic parameters: serum concentrations determined by a new high-performance liquid chromatographic technique. Antimicrob Agents Chemother. 21(1):170–172. doi: 10.1128/AAC.21.1.170.
   PubMed Web of Science ®Google Scholar
• Rubin K, Sullivan D, Sadhasivam S. 2009. Are peripheral and neuraxial blocks with ultrasound guidance more effective and safe in children? Paediatr Anaesth. 19(2):92–96. doi: 10.1111/j.1460-9592.2008.02918.x.
   PubMed Web of Science ®Google Scholar
• Santoro J, Agarwal B, Martinelli R, Wenger N, Levison ME. 1978. Pharmacology of cefaclor in normal volunteers and patients with renal failure. Antimicrob Agents Chemother. 13(6):951–954. doi: 10.1128/AAC.13.6.951.
   PubMed Web of Science ®Google Scholar
• Sen A. 2008. Recurrent cystitis in non-pregnant women. BMJ Clin Evid. 2008:0801.
   PubMedGoogle Scholar
• Soliman ABE, Pawluk SA, Wilby KJ, Rachid O. 2022. The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies. Int J Clin Pharm. 44(4):894–903. doi: 10.1007/s11096-022-01390-y.
   PubMed Web of Science ®Google Scholar
• Spasić A, Homšek I. 2010. Influence of dissolution media composition on cefaclor release form capsules. Sci. Pharm. 78(3):610–610. doi: 10.3797/scipharm.cespt.8.PDD21.
   Google Scholar
• Spyker DA, Gober LL, Scheld WM, Sande MA, Bolton W. 1982. Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis. Antimicrob Agents Chemother. 21(2):278–281. doi: 10.1128/AAC.21.2.278.
   PubMed Web of Science ®Google Scholar
• Spyker DA, Thomas BL, Sande MA, Bolton WK. 1978. Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function. Antimicrob Agents Chemother. 14(2):172–177. doi: 10.1128/AAC.14.2.172.
   PubMed Web of Science ®Google Scholar
• Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, Huy NT. 2019. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 47(1):46. doi: 10.1186/s41182-019-0165-6.
   PubMedGoogle Scholar
• Tutunji M, Jarrar O, Musameh M, Alam SM, Dham R. Quamruzaman 2001. Bioequivalence evaluation of two brands of cefaclor 500 mg capsules: quantification of cefaclor using solid phase extraction technique. J Clin Pharm Ther. 26(2):149–153. doi: 10.1046/j.1365-2710.2001.00337.x.
   PubMed Web of Science ®Google Scholar
• Wilson R. 1993. Cefaclor. Int J Antimicrob Agents. 2(3):185–198. doi: 10.1016/0924-8579(93)90053-8.
   PubMedGoogle Scholar